tiotropium olodaterol Stiolto Respimat
Selected indexed studies
- Tiotropium/olodaterol (Stiolto Respimat) for COPD. (Med Lett Drugs Ther, 2015) [PMID:26583607]
- Tiotropium/Olodaterol: A Review in COPD. (Drugs, 2019) [PMID:31119643]
- Tiotropium/Olodaterol: A Review in COPD. (Drugs, 2016) [PMID:26683033]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tiotropium/Olodaterol: A Review in COPD. (2016) pubmed
- Tiotropium/Olodaterol: A Review in COPD. (2019) pubmed
- Drugs for COPD. (2020) pubmed
- Drugs for COPD. (2024) pubmed
- Tiotropium/olodaterol (Stiolto Respimat) for COPD. (2015) pubmed
- Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. (2016) pubmed
- [Spiolto Respimat® : tiotropium-olodaterol fixed combination for therapy of chronic obstructive pulmonary disease (COPD)]. (2016) pubmed
- Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies. (2018) pubmed
- Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. (2017) pubmed
- Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO(®)/DYNAGITO(®) Trials. (2020) pubmed